1. Triterpenic Acid Amides as a Promising Agent for Treatment of Metabolic Syndrome
- Author
-
Nariman F. Salakhutdinov, Sergey Kuranov, Olga A. Luzina, V. V. Fomenko, Marina S. Borisova, Tatyana G. Tolstikova, M. V. Khvostov, D. S. Baev, and Mikhail Blokhin
- Subjects
natural product ,type 2 diabetes mellitus ,glucose tolerance ,Pharmaceutical Science ,lcsh:RS1-441 ,Pharmacology ,lcsh:Pharmacy and materia medica ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Total cholesterol ,medicine ,triterpenic amides ,030304 developmental biology ,Glycemic ,0303 health sciences ,Natural product ,total cholesterol ,medicine.disease ,chemistry ,030220 oncology & carcinogenesis ,hypoglycemic activity ,lipids (amino acids, peptides, and proteins) ,Animal studies ,Metabolic syndrome ,Pharmacophore ,Derivative (chemistry) - Abstract
A series of triterpenic acid amides were synthesized incorporating a 2-ethoxy-3-phenylpropanoic acid pharmacophore fragment. The synthesized compounds were tested for their ability to improve glycemic control and to counter lipid abnormalities in C57BL/6 mice placed on a high-fat/high-cholesterol diet. Of all tested compounds, the dihydrobetulonic derivative (16b) had the most pronounced effect in decreasing blood glucose levels, total cholesterol (TC), and high-density lipoproteins (HDL). All the synthesized compounds displayed a relatively safe profile in the animal studies carried out in this work.
- Published
- 2021